The technology involves preparing the vaccine from pooled partially purified soluble melanoma antigens shed from 3 human melanoma cell lines during tissue culture. The tumor cell lines are grown in defined conditions and the liquid surrounding them is removed, concentrated and partially purified. Multiple doses of the vaccine are then injected into the patient in a regimen together with the adjuvant, aluminum hydroxide (alum).

Cancer vaccines are designed to elicit both humoral and cell based immune responses. Seviprotimut-L elicits both humoral and cell based anti-tumor immunity. Clinical trials have shown that protective immunity is based in part on CD8+ T cell and antibody responses. Cellular immune responses can be induced in patients with various genetic (HLA) genotypes, which allows the vaccine to be used for all patients regardless of HLA type. There is evidence of an association between vaccine induced antibody and cellular immune responses against specific antigens and improved clinical survival data. This substantiates the scientific basis of the vaccine and links the clinical outcome with vaccine induced immunity, which can be tracked during treatment.